City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) Director Robert Nelsen purchased 170,000 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the transaction, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
City Therapeutics Stock Down 4.2%
Shares of NASDAQ:CTY traded down $0.94 during trading on Monday, reaching $21.46. 302,365 shares of the company’s stock traded hands. City Therapeutics, Inc. has a 12 month low of $20.50 and a 12 month high of $23.88.
About City Therapeutics
See Also
- Five stocks we like better than City Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
